 Jason Kolfenbach
Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatology | 12 | 2026 | 133 | 3.260 |
Why?
| | Rheumatic Diseases | 5 | 2026 | 97 | 1.950 |
Why?
| | Takayasu Arteritis | 1 | 2025 | 16 | 0.900 |
Why?
| | Non-ST Elevated Myocardial Infarction | 1 | 2025 | 26 | 0.880 |
Why?
| | Remote Consultation | 1 | 2026 | 66 | 0.870 |
Why?
| | Arthritis, Rheumatoid | 9 | 2023 | 1170 | 0.830 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 465 | 0.690 |
Why?
| | Telemedicine | 5 | 2026 | 957 | 0.550 |
Why?
| | Education, Medical, Graduate | 5 | 2026 | 562 | 0.520 |
Why?
| | Health Services Accessibility | 1 | 2026 | 1098 | 0.510 |
Why?
| | Triage | 1 | 2019 | 249 | 0.480 |
Why?
| | Fellowships and Scholarships | 4 | 2026 | 355 | 0.420 |
Why?
| | Autoantibodies | 6 | 2015 | 1505 | 0.420 |
Why?
| | Connective Tissue Diseases | 1 | 2011 | 84 | 0.320 |
Why?
| | Hydrolases | 1 | 2010 | 55 | 0.310 |
Why?
| | Myelitis | 1 | 2011 | 107 | 0.310 |
Why?
| | Granulomatosis with Polyangiitis | 2 | 2020 | 47 | 0.300 |
Why?
| | Neuromyelitis Optica | 1 | 2011 | 137 | 0.300 |
Why?
| | Antirheumatic Agents | 2 | 2023 | 304 | 0.300 |
Why?
| | Family Health | 1 | 2009 | 191 | 0.290 |
Why?
| | Peptides, Cyclic | 5 | 2015 | 275 | 0.270 |
Why?
| | Rheumatoid Factor | 4 | 2015 | 178 | 0.260 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2025 | 677 | 0.250 |
Why?
| | Scleroderma, Diffuse | 1 | 2025 | 10 | 0.220 |
Why?
| | Problem-Based Learning | 1 | 2026 | 97 | 0.220 |
Why?
| | Formative Feedback | 1 | 2025 | 35 | 0.220 |
Why?
| | Drug-Eluting Stents | 1 | 2025 | 88 | 0.210 |
Why?
| | Musculoskeletal Diseases | 1 | 2025 | 90 | 0.210 |
Why?
| | Physical Examination | 1 | 2025 | 240 | 0.210 |
Why?
| | Echocardiography, Transesophageal | 1 | 2025 | 132 | 0.210 |
Why?
| | Curriculum | 4 | 2023 | 1063 | 0.210 |
Why?
| | Immunosuppressive Agents | 3 | 2025 | 834 | 0.200 |
Why?
| | Humans | 28 | 2026 | 144671 | 0.190 |
Why?
| | Coronary Angiography | 1 | 2025 | 324 | 0.190 |
Why?
| | Coronary Artery Bypass | 1 | 2025 | 267 | 0.190 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 4 | 0.190 |
Why?
| | Corneal Ulcer | 1 | 2022 | 20 | 0.180 |
Why?
| | Scleritis | 1 | 2022 | 28 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 2 | 2012 | 2350 | 0.180 |
Why?
| | Methotrexate | 3 | 2021 | 231 | 0.180 |
Why?
| | Adult | 12 | 2026 | 40489 | 0.180 |
Why?
| | Electrocardiography | 1 | 2025 | 664 | 0.170 |
Why?
| | Rheumatologists | 2 | 2023 | 15 | 0.170 |
Why?
| | Program Evaluation | 1 | 2026 | 941 | 0.170 |
Why?
| | Educational Status | 1 | 2023 | 463 | 0.170 |
Why?
| | Autoimmunity | 3 | 2012 | 930 | 0.170 |
Why?
| | Aftercare | 1 | 2021 | 222 | 0.150 |
Why?
| | Referral and Consultation | 1 | 2026 | 852 | 0.150 |
Why?
| | Female | 15 | 2026 | 78304 | 0.150 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2025 | 547 | 0.150 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 238 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2020 | 101 | 0.150 |
Why?
| | Middle Aged | 10 | 2026 | 35971 | 0.130 |
Why?
| | Electronic Health Records | 1 | 2026 | 1176 | 0.130 |
Why?
| | Patient Selection | 2 | 2019 | 727 | 0.130 |
Why?
| | Behcet Syndrome | 1 | 2016 | 19 | 0.120 |
Why?
| | Ophthalmologists | 1 | 2016 | 17 | 0.120 |
Why?
| | Azathioprine | 1 | 2016 | 44 | 0.120 |
Why?
| | Patient Readmission | 1 | 2021 | 765 | 0.120 |
Why?
| | Arthritis, Juvenile | 1 | 2016 | 58 | 0.110 |
Why?
| | Colorado | 1 | 2026 | 4558 | 0.110 |
Why?
| | Eye Diseases | 1 | 2016 | 95 | 0.110 |
Why?
| | Glucocorticoids | 2 | 2016 | 528 | 0.110 |
Why?
| | Drug Costs | 1 | 2016 | 117 | 0.110 |
Why?
| | Uveitis | 1 | 2016 | 149 | 0.110 |
Why?
| | Vision Disorders | 1 | 2016 | 179 | 0.110 |
Why?
| | Male | 11 | 2026 | 72431 | 0.100 |
Why?
| | Delphi Technique | 2 | 2025 | 330 | 0.100 |
Why?
| | United States | 3 | 2026 | 16018 | 0.100 |
Why?
| | Disease Progression | 2 | 2011 | 2847 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1287 | 0.090 |
Why?
| | Health Care Costs | 1 | 2016 | 425 | 0.090 |
Why?
| | Clinical Competence | 3 | 2026 | 1237 | 0.090 |
Why?
| | Bronchial Diseases | 1 | 2011 | 38 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2025 | 296 | 0.090 |
Why?
| | Chemokines | 1 | 2012 | 218 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 835 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2012 | 420 | 0.080 |
Why?
| | Internship and Residency | 1 | 2022 | 1262 | 0.080 |
Why?
| | Protein-Arginine Deiminases | 1 | 2010 | 16 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1360 | 0.080 |
Why?
| | Risk Factors | 4 | 2025 | 10796 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1961 | 0.080 |
Why?
| | Patient Care Planning | 1 | 2011 | 170 | 0.080 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2009 | 48 | 0.080 |
Why?
| | Prospective Studies | 3 | 2025 | 7994 | 0.060 |
Why?
| | Aged | 6 | 2025 | 25955 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2660 | 0.060 |
Why?
| | Antilymphocyte Serum | 1 | 2025 | 56 | 0.050 |
Why?
| | Lung Diseases | 1 | 2011 | 781 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2117 | 0.050 |
Why?
| | Feedback | 1 | 2025 | 181 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2025 | 265 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 120 | 0.050 |
Why?
| | Cohort Studies | 2 | 2012 | 5957 | 0.050 |
Why?
| | Inflammation | 2 | 2012 | 2870 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 475 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2942 | 0.050 |
Why?
| | Biological Factors | 1 | 2022 | 39 | 0.050 |
Why?
| | Focus Groups | 1 | 2025 | 566 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2137 | 0.040 |
Why?
| | Accreditation | 1 | 2022 | 101 | 0.040 |
Why?
| | Contraceptive Agents | 1 | 2021 | 65 | 0.040 |
Why?
| | Needs Assessment | 1 | 2023 | 401 | 0.040 |
Why?
| | Oximes | 1 | 2020 | 26 | 0.040 |
Why?
| | Young Adult | 2 | 2021 | 14122 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 7140 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 125 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1995 | 0.040 |
Why?
| | Internal Medicine | 1 | 2022 | 278 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2020 | 303 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 190 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 211 | 0.040 |
Why?
| | Contraception | 1 | 2021 | 170 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 246 | 0.040 |
Why?
| | Biomarkers | 1 | 2009 | 4261 | 0.030 |
Why?
| | Pyridones | 1 | 2020 | 201 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 224 | 0.030 |
Why?
| | Adolescent | 2 | 2021 | 22409 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11735 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3414 | 0.030 |
Why?
| | Administration, Topical | 1 | 2016 | 152 | 0.030 |
Why?
| | Specialization | 1 | 2016 | 136 | 0.030 |
Why?
| | Ophthalmology | 1 | 2016 | 116 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 537 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 160 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1700 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 308 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 6041 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 360 | 0.020 |
Why?
| | Interleukin-9 | 1 | 2012 | 12 | 0.020 |
Why?
| | Arthrography | 1 | 2011 | 18 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 161 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2012 | 438 | 0.020 |
Why?
| | Joints | 1 | 2011 | 107 | 0.020 |
Why?
| | Patient Care Team | 1 | 2016 | 690 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 781 | 0.020 |
Why?
| | Decision Making | 1 | 2016 | 973 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2012 | 770 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 7122 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2114 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 2045 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3147 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2021 | 17149 | 0.010 |
Why?
| | Child | 1 | 2016 | 22600 | 0.010 |
Why?
|
|
Kolfenbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|